The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

Please provide your email address to receive an email when new articles are posted on . Omalizumab reduced exacerbations by 93% over 6 years. Dupilumab significantly improved quality of life.

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...

The latest advances in asthma care combine revolutionary biologics, individualized immunotherapy, and targeted treatments that address specific triggers, ditching the “one-size-fits-all” approach. The ...

Biologic therapies for asthma and CRSwNP may reduce ear-related symptoms, including otitis media, ear fullness, pain, and dizziness. A retrospective analysis showed significant improvements in ...

Improvement across all asthma control parameters was achieved after 12 months of biologic treatment, according to one study. Patients with severe asthma treated with either omalizumab, benralizumab, ...

Biologics used as an asthma treatment also appear to improve symptoms of coexisting chronic rhinosinusitis in some patients, according to results from a real-world study published in the International ...

Adherence to biologic agents for the treatment of moderate to severe asthma varies according to where patients have their shots administered. Adherence rates are lower among those who are always ...